Xenon Pharmaceuticals Inc [XENE] stock is trading at $33.16, up 8.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The XENE shares have gain 7.07% over the last week, with a monthly amount drifted -0.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xenon Pharmaceuticals Inc [NASDAQ: XENE] stock has seen the most recent analyst activity on May 07, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $55. Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $67. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $53 on October 01, 2024. Citigroup initiated its recommendation with a Buy and recommended $62 as its price target on January 04, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on December 08, 2023, and assigned it a price target of $63.
Xenon Pharmaceuticals Inc [XENE] stock has fluctuated between $26.74 and $46.00 over the past year. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $33.16 at the most recent close of the market. An investor can expect a potential return of 26.66% based on the average XENE price forecast.
Analyzing the XENE fundamentals
Gross Profit Margin for this corporation currently stands at -0.09% with Operating Profit Margin at -39.07%, Pretax Profit Margin comes in at -34.07%, and Net Profit Margin reading is -33.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.32 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Xenon Pharmaceuticals Inc’s Current Ratio is 17.66. On the other hand, the Quick Ratio is 17.66, and the Cash Ratio is 13.45. Considering the valuation of this stock, the price to sales ratio is 339.27, the price to book ratio is 3.61.
Transactions by insiders
Recent insider trading involved GANNON STEVEN, Director, that happened on Jun 05 ’25 when 3.0 shares were sold. PRESIDENT & CEO, MORTIMER IAN completed a deal on Jan 24 ’25 to sell 22468.0 shares. Meanwhile, PRESIDENT & CEO MORTIMER IAN sold 16315.0 shares on Jan 27 ’25.
